TY - JOUR
T1 - Leroy walters’s legacy of bioethics in genetics and biotechnology policy
AU - Cook-Deegan, Robert
AU - McCormack, Stephen J.
N1 - Funding Information:
Supported in part by grants from the National Human Genome Research Institute (P50 HG 003391, R01 HG 008918), and supplemental funding from the Department of Energy, Marion Kauffman Foundation, and FasterCures, a Center of the Milken Institute. We thank research assistant Abhiram Sanka for tracking down and inserting references. The views do not reflect those of the funding institutions.
Funding Information:
The DPD was incorporated into Duke’s Center for Public Genomics in 2004, funded by a grant from the National Human Genome Research Institute (P50 HG003391), with LeRoy Walters as Principal Investigator of the DPD core, and Doris Goldstein his co-Investigator. The DPD remained a freely available international database until 2016, when that grant expired and search technology made the need for a specific database of DNA patents less important. The search algorithm became a tool that was modified for studies of DNA patents (Bubela, Vishnubhakat, and Cook-Deegan 2015; Cook-Deegan, Vishnubhakat, and Bubela 2016). The existence of the DNA Patent Database and the studies it enabled were attributable in no small part to the persistence of one LeRoy Walters.
Publisher Copyright:
© 2019 by Johns Hopkins University Press.
PY - 2019/3
Y1 - 2019/3
N2 - LeRoy Walters was at the center of public debate about emerging biological technologies, even as "biotechnology" began to take root. He chaired advisory panels on human gene therapy, the human genome project, and patenting DNA for the congressional Office of Technology Assessment. He chaired the subcommittee on Human Gene Therapy for NIH's Recombinant DNA Advisory Committee. He was also a regular advisor to Congress, the executive branch, and academics concerned about policy governing emerging biotechnologies. In large part due to Prof. Walters, the Kennedy Institute of Ethics was one of the primary sources of talent in bioethics, including staff who populated policy and science agencies dealing with reproductive and genetic technologies, such as NIH and OTA. His legacy lies not only in his writings, but in those people, documents, and discussions that guided biotechnology policy in the United States for three decades.
AB - LeRoy Walters was at the center of public debate about emerging biological technologies, even as "biotechnology" began to take root. He chaired advisory panels on human gene therapy, the human genome project, and patenting DNA for the congressional Office of Technology Assessment. He chaired the subcommittee on Human Gene Therapy for NIH's Recombinant DNA Advisory Committee. He was also a regular advisor to Congress, the executive branch, and academics concerned about policy governing emerging biotechnologies. In large part due to Prof. Walters, the Kennedy Institute of Ethics was one of the primary sources of talent in bioethics, including staff who populated policy and science agencies dealing with reproductive and genetic technologies, such as NIH and OTA. His legacy lies not only in his writings, but in those people, documents, and discussions that guided biotechnology policy in the United States for three decades.
UR - http://www.scopus.com/inward/record.url?scp=85066061604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066061604&partnerID=8YFLogxK
U2 - 10.1353/ken.2019.0010
DO - 10.1353/ken.2019.0010
M3 - Article
C2 - 31080177
AN - SCOPUS:85066061604
SN - 1054-6863
VL - 29
SP - 51
EP - 66
JO - Kennedy Institute of Ethics journal
JF - Kennedy Institute of Ethics journal
IS - 1
ER -